164 related articles for article (PubMed ID: 12660660)
1. Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel?
Malinin AI; O'Connor CM; Dzhanashvili AI; Sane DC; Serebruany VL
Am Heart J; 2003 Mar; 145(3):397-403. PubMed ID: 12660660
[TBL] [Abstract][Full Text] [Related]
2. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial.
Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM
Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328
[TBL] [Abstract][Full Text] [Related]
3. Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity?
Malinin AI; Oshrine BR; Sane DC; O'Connor CM; Serebruany VL
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):91-6. PubMed ID: 17287623
[TBL] [Abstract][Full Text] [Related]
4. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
5. Platelet ADP receptor antagonists: ticlopidine and clopidogrel.
Jacobson AK
Best Pract Res Clin Haematol; 2004 Mar; 17(1):55-64. PubMed ID: 15171957
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA
Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929
[TBL] [Abstract][Full Text] [Related]
8. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Reaume KT; Regal RE; Dorsch MP
Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel resistance?
Gurbel PA; Tantry US
Thromb Res; 2007; 120(3):311-21. PubMed ID: 17109936
[TBL] [Abstract][Full Text] [Related]
10. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
11. The role of clopidogrel in the management of ischemic heart disease.
Galla JM; Lincoff AM
Curr Opin Cardiol; 2007 Jul; 22(4):273-9. PubMed ID: 17556877
[TBL] [Abstract][Full Text] [Related]
12. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
13. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.
Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Alfonso F; Macaya C; Bass TA; Costa MA
J Am Coll Cardiol; 2007 Apr; 49(14):1505-16. PubMed ID: 17418288
[TBL] [Abstract][Full Text] [Related]
14. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
15. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
17. What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?
Steinhubl S; Berger P
Am Heart J; 2003 Jun; 145(6):971-8. PubMed ID: 12796751
[TBL] [Abstract][Full Text] [Related]
18. Aspirin and clopidogrel resistance: possible mechanisms and clinical relevance. Part I: Concept of resistance.
Vadász D; Sztriha LK; Sas K; Vecsei L
Ideggyogy Sz; 2012 Nov; 65(11-12):377-85. PubMed ID: 23289172
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
20. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
